Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China

BACKGROUND: Diffuse large B‐cell lymphoma (DLBCL) patients refractory to rituximab‐based immunochemotherapy have a dismal prognosis. However, the definition of refractory DLBCL remains inconsistent and no large cohort study data is available from Asian countries. To validate the definition and outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuo, Wang, Li, Hu, Jianda, Qian, Wenbin, Zhang, Xi, Hu, Yu, Zhu, Qi, Chen, Bobin, Wu, Depei, Chang, Chung‐Chou H., Xu, Pengpeng, Zheng, Xiaoyun, Wei, Juying, Liu, Yao, Cui, Guohui, Tang, Yong, Ma, Yan, Huang, Haiwen, Yi, Hongmei, Zhao, Weili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968882/
https://www.ncbi.nlm.nih.gov/pubmed/33482051
http://dx.doi.org/10.1002/cac2.12126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968882/
https://www.ncbi.nlm.nih.gov/pubmed/33482051
http://dx.doi.org/10.1002/cac2.12126

Ejemplares similares